Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 47

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 47
---
pliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period, whereupon the Company is required to take reasonably appropriate action to recover all erroneously awarded incentive compensation received by an executive during the three year period preceding the required accounting restatement and during any transition period (that results from a change in the Company’s fiscal year) within or immediately following such three year period. During 2024, the Company was not required to prepare an accounting restatement that required recovery of erroneously awarded compensation pursuant to the Company’s Incentive Compensation Recoupment Policy nor was there an outstanding balance as of the end of the last completed fiscal year of erroneously awarded compensation to be recovered from the application of the policy to a prior restatement. 30 Share Ownership and Retention Guidelines The Compensation Committee of the Board of Directors recommended, and the Board of Directors adopted, Share Ownership and Retention Guidelines for the Board of Directors and the CEO (the “Guidelines”). Under the Guidelines, each director is required to hold $150,000 of Company stock, and the CEO is required to hold Company stock equal to three times his base salary. The Guidelines were adopted in 2020 and allow each director and the CEO five years to attain the required ownership of Company stock. The Guidelines do not currently have share ownership or retention requirements applicable to other employees or NEOs. Tax Considerations Section 162(m) of the Internal Revenue Code (“Section 162(m)”) imposes an annual deduction limit of $1 million on the amount of compensation paid to the Company’s executive officers. Although the Compensation Committee will continue to consider tax implications as one factor in determining executive compensation, the Compensation Committee also looks at other factors in making its decisions and retains the flexibility to provide compensation for the Company’s CEO and other NEOs in a manner consistent with the goals of our executive compensation program and the best interests of Supernus and its shareholders, which may include providing for compensation that is not deductible by Supernus due to the deduction limit under Section 162(m). Anti-Hedging and Anti-Pledging Policies Our Insider Trading Policy generally prohibits our directors, CEO, other NEOs and all other employees from entering into hedging or monetization transactions that transfer, with respect to equity compensation received by such individual, all